New protein kinase inhibitors in breast cancer: afatinib and neratinib

Bibliography

• GLOBOCAN 2012
   Google Scholar
• Int Cancer Facts & Figures 2013. American Cancer Society, Atlanta; 2013
   Google Scholar
• Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64(1):52-62
   PubMed Web of Science ®Google Scholar
• Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200(3):290-7
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
   PubMed Web of Science ®Google Scholar
• Paik S, Liu ET. HER2 as a predictor of therapeutic response in breast cancer. Breast Dis 2000;11:91-102
   PubMedGoogle Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45
   PubMed Web of Science ®Google Scholar
• Nielsen DL, Kümler I, Palshof JA, Andersson M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013;22(1):1-12
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 2007;357(1):39-51
   PubMed Web of Science ®Google Scholar
• Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005;20(3):1005-15
   PubMed Web of Science ®Google Scholar
• Fralick M, Hilton JF, Bouganim N, et al. Dual blockade of HER2 - twice as good or twice as toxic? Clin Oncol 2012;24:593-603
   Web of Science ®Google Scholar
• Baselga J, Albanell J, Molina MA, et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001;28(Suppl 16):4-11
   PubMedGoogle Scholar
• Ladoire S, Arnould L, Mignot G, et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 2011;105(3):366-71
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10(17):5650-5
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94(2):259-67
   PubMed Web of Science ®Google Scholar
• Beano A, Signorino E, Evangelista A, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008;6:25
   Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-48
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
   PubMed Web of Science ®Google Scholar
• Gasparini G, Gion M, Mariani L, et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007;101(3):355-65
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69(24):9330-6
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(1):25-32
   PubMed Web of Science ®Google Scholar
• Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128(2):347-56
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28(16):2698-704
   PubMed Web of Science ®Google Scholar
• Tsang R, Sadeghi S, Finn R. Lapatinib, a dual-targeted small molecule inhibitor of Egfr and Her2, in Her2-amplified breast cancer: from bench to bedside. Clin Med Insights 2011;3:1-13
   Google Scholar
• Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1(2):85-94
   PubMed Web of Science ®Google Scholar
• Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008;65(18):1703-10
   PubMed Web of Science ®Google Scholar
• Moy B, Kirkpatrick P, Kar S, et al. Lapatinib. Nat Rev Drug Discov 2007;6(6):431-2
   PubMed Web of Science ®Google Scholar
• Morikawa A, Peereboom D, Smith Q, et al. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol 2013;31(15 Suppl):514
   Web of Science ®Google Scholar
• Perez E, Byrne J, Hammond I, et al. Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol 2006;17(Suppl 9):A1420
   Google Scholar
• Maruyama T, Mimura K, Izawa S, et al. Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression. Anticancer Res 2011;31(9):2999-3005
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533-43
   PubMed Web of Science ®Google Scholar
• Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26(12):1993-9
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013;14(1):64-71
   PubMed Web of Science ®Google Scholar
• Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol 2014;16(1):276
   PubMed Web of Science ®Google Scholar
• Pivot X, Semiglazov V, Żurawski B, et al. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer [abstract]. ESMO 2012
   Google Scholar
• Gelmon KA, Boyle F, Kaufman B, et al. An open-label, randomized, phase III trial comparing taxane-based chemotherapy with lapatinib or trastuzumab as a first-line therapy for women with HER2-positive metastatic breast cancer. J Clin Oncol 2012;30(18 Suppl):LBA671
   Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379(9816):633-40
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol 2013;72(6):1213-22
   PubMed Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28(25):3965-72
   PubMed Web of Science ®Google Scholar
• Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012;133(3):1057-65
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Stomiolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28(7):1124-30
   PubMed Web of Science ®Google Scholar
• Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2012;134(3):1149-59
   PubMed Web of Science ®Google Scholar
• Ellis M, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006;24:3019-25
   PubMed Web of Science ®Google Scholar
• Gunzer K, de Mont-Serrat H, Uttenreuther-Fischer MM, et al. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy. J Clin Oncol 2010;28(15 Suppl):1072
   Web of Science ®Google Scholar
• Wissner A, Mansour T. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm Chem Life Sci 2008;341:465-77
   PubMed Web of Science ®Google Scholar
• Rabindran S, Discafani C, Rosfjord E, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65
   PubMed Web of Science ®Google Scholar
• Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552-8
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28(18):3076-83
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28(8):1301-7
   PubMed Web of Science ®Google Scholar
• Canonici A, Gijsen M, Mullooly M, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 2013;4(10):1592-605
   PubMed Web of Science ®Google Scholar
• Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 2009;27(15S):abstract 1004
   Google Scholar
• Martin M, Bonneterre J, Geyer CE Jr, et al. A phase two randomized trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013;49(18):3763-72
   PubMed Web of Science ®Google Scholar
• Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with ErbB2-positive breast cancer. Cancer Res 2011;71(24 Suppl):abstract P1-12-09
   Google Scholar
• Chow LWC, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer 2013;108:1985-93
   PubMed Web of Science ®Google Scholar
• Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol 2013;72(6):1205-12
   PubMed Web of Science ®Google Scholar
• Awada A, Dirix L, Sanchez LM, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2013;24:109-16
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011;11(2):263-75
   PubMed Web of Science ®Google Scholar
• Gajria D, King T, Pannu H, et al. Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer. Cancer Res 2012;72(24 Suppl):abstract nr P5-18-04
   Google Scholar
• Mullooy M, O’Brien NA, Conlin D, et al. Preclinical studies with neratinib in triple-negative breast cancer. J Clin Oncol 2013;31(Suppl):abstract 1054
   Google Scholar
• Weil R, Palmieri D, Bronder J, et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167(4):913-20
   PubMed Web of Science ®Google Scholar
• Montagna E, Cancello G, D’Agostino D, et al. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol 2009;63(2):275-80
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs 2007;18:23-8
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Human epidermal growth factor receptor 2–positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86
   PubMed Web of Science ®Google Scholar
• Polli J, Humphreys J, Harmon K, et al. The role of efflux and uptake transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl) ethyl] amino}methyl) -2-furyl]-4-quinazolinamine (GW572016, Lapatinib) disposition and drug interactions. Drug Metab Disposition 2008;36(4):695-701
   PubMed Web of Science ®Google Scholar
• Seyhan A, Varadarajan U, Choe S, et al. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. Mol Bio Syst 2011;7:1974-89
   Google Scholar
• Hegedüs C, Truta-Feles K, Antalffy G, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol 2012;84(3):260-7
   PubMed Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 2013;29(8):1015-24
   PubMed Web of Science ®Google Scholar
• Teng YH, Tan WJ, Thike AA, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011;13(2):R35
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3(2):224-37
   PubMed Web of Science ®Google Scholar
• X Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010;15(9):924-34
   PubMed Web of Science ®Google Scholar
• Xx Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71
   PubMed Web of Science ®Google Scholar